
CLAIMS

1. Use of ~~A~~a compound of the following formula (I)




(I)


wherein


- R1 is a hydrogen atom or a halogen atom;
- R2 is a cyclohexyle or a phenyl;
- R3is a cycloalkyl having 3 to 6 carbon atoms;
- R4 is a hydrogen atom, an alkyl having 1 to 6 carbon atom or acycloalkyl having 3 to 6 carbon atoms;
- A is a group selected from –CO-CH_2-, -CH(Cl)-CH_2-, -CH(OH)-CH_2-, -CH_2-CH_2-, -CH=CH-, -C≡C-~~,~~


or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof in the manufacture of a medicament for ~~for use in the prevention or treatment of~~ preventing or treating an infection by a virus in an individual.


2. The use according to claim 1, wherein ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for used according to claim 1,~~ wherein the compound of formula (I) is selected from the group consisting of:



Cl
N



Cl
N



Cl
N



Cl
N
O


Cl
N


Cl
N







3. The ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for used~~ use according to claim 1 or 2, wherein the compound of formula (I) is SR-31747.

4. The ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 3, wherein the virus is of the *Coronaviridae* family, more particularly of the *Betacoronavirus* genus.

5. The ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 4, wherein the virus is selected from the group consisting of SARS-CoV, SARS-CoV-2, MERS-CoV and mutants or variants thereof.

6. The ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 5, wherein the virus is SARS-CoV-2, or a mutant or variant thereof.

7. The ~~The compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 6, wherein the individual is aged 50 or more.

8. The ~~compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 7, wherein the individual suffers from at least one other disease or condition, in particular selected from hypertension, diabetes, a cardiovascular disease, a chronic respiratory disease, or cancer.

9. The ~~compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof for~~ use according to any one of claims 1 to 8, wherein the medicament is to be administered in combination with at least one other compound suitable for the prevention or treatment of an infection by a virus.

10. The use of ~~A~~a pharmaceutical composition, comprising as active substance a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in the manufacture of a medicament for ~~use in the prevention or treatment~~ preventing or treating~~of~~ an infection by a virus in an individual.

11. The ~~pharmaceutical composition for~~ use according to claim 10, wherein the virus is of the *Coronaviridae* family, more particularly of the *Betacoronavirus* genus.

12. The ~~pharmaceutical composition for~~ use according to claim 10 or 11, wherein the virus is selected from the group consisting of SARS-CoV, SARS-CoV-2, MERS-CoV and mutants or variants thereof.

13. The ~~pharmaceutical composition for~~ use according to any one of claims 10 to 12, wherein the virus is SARS-CoV-2, or a mutant or variant thereof.

14. The ~~pharmaceutical composition for~~ use according to any one of claims 10 to 13, further comprising at least one other compound suitable for the prevention or treatment of an infection by a virus.

15. Use of a ~~Products containing~~ product comprising:
- a compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof, and
- at least one other compound suitable for the prevention or treatment of an infection by a virus,

in a preparation of ~~as a combined preparation~~ a combined medicament for simultaneous, separate, or sequential use in the prevention or treatment of an infection by a virus in an individual.